Overview

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is: - To see if polyTregs can reduce inflammation in a transplanted kidney. - To find out what effects, good or bad, polyTregs will have in the kidney recipient. - To find out what effects, good or bad, taking everolimus after polyTregs will have in the kidney recipient.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Clinical Trials in Organ Transplantation
Treatments:
Acetaminophen
Calcineurin Inhibitors
Diphenhydramine
Everolimus
Mycophenolate mofetil
Mycophenolic Acid
Promethazine
Sirolimus
Tacrolimus